Bortezomib treatment exposure and grade 3/4 adverse events reported during treatment
| . | Once-weekly bortezomib (n = 369) . | Twice-weekly bortezomib (n = 134) . | P . |
|---|---|---|---|
| Bortezomib exposure | |||
| Cumulative planned dose, mg/m2 | 46.8 | 67.6 | |
| Median cumulative dose delivered, mg/m2 (IQR) | 39.4 (22.2-45.5) | 40.1 (26.3-52.0) | .65 |
| Percentage of planned dose delivered, % | 84 | 59 | |
| Patients who received ≥ 90% of planned dose, n (%) | 144 (39) | 17 (13) | < .001 |
| Adverse events, n (%) | |||
| Hematologic events | 161 (44) | 60 (45) | .83 |
| Neutropenia | 120 (33) | 46 (34) | .74 |
| Thrombocytopenia | 69 (19) | 35 (26) | .08 |
| Anemia | 38 (10) | 12 (9) | .74 |
| Nonhematologic events | 131 (35) | 68 (51) | .003 |
| Infections | 41 (11) | 14 (10) | > .999 |
| Cardiac events | 31 (8) | 9 (7) | .70 |
| Neuropathy | 30 (8) | 38 (28) | < .001 |
| Sensory | 11 (3) | 22 (16) | < .001 |
| Neuralgia | 10 (3) | 6 (5) | .25 |
| Sensory and neuralgia | 9 (3) | 10 (8) | .01 |
| Gastrointestinal events | 22 (6) | 15 (11) | .08 |
| Systemic events | 14 (4) | 10 (7) | .09 |
| Vascular events | 13 (4) | 5 (4) | > .999 |
| Deep-vein thrombosis/pulmonary embolism | 12 (3) | 5 (4) | .78 |
| Dermatologic events | 6 (2) | 9 (7) | .006 |
| Bleeding | 1 (< 1) | 1 (< 1) | .46 |
| Other conditions | 22 (6) | 5 (4) | .66 |
| . | Once-weekly bortezomib (n = 369) . | Twice-weekly bortezomib (n = 134) . | P . |
|---|---|---|---|
| Bortezomib exposure | |||
| Cumulative planned dose, mg/m2 | 46.8 | 67.6 | |
| Median cumulative dose delivered, mg/m2 (IQR) | 39.4 (22.2-45.5) | 40.1 (26.3-52.0) | .65 |
| Percentage of planned dose delivered, % | 84 | 59 | |
| Patients who received ≥ 90% of planned dose, n (%) | 144 (39) | 17 (13) | < .001 |
| Adverse events, n (%) | |||
| Hematologic events | 161 (44) | 60 (45) | .83 |
| Neutropenia | 120 (33) | 46 (34) | .74 |
| Thrombocytopenia | 69 (19) | 35 (26) | .08 |
| Anemia | 38 (10) | 12 (9) | .74 |
| Nonhematologic events | 131 (35) | 68 (51) | .003 |
| Infections | 41 (11) | 14 (10) | > .999 |
| Cardiac events | 31 (8) | 9 (7) | .70 |
| Neuropathy | 30 (8) | 38 (28) | < .001 |
| Sensory | 11 (3) | 22 (16) | < .001 |
| Neuralgia | 10 (3) | 6 (5) | .25 |
| Sensory and neuralgia | 9 (3) | 10 (8) | .01 |
| Gastrointestinal events | 22 (6) | 15 (11) | .08 |
| Systemic events | 14 (4) | 10 (7) | .09 |
| Vascular events | 13 (4) | 5 (4) | > .999 |
| Deep-vein thrombosis/pulmonary embolism | 12 (3) | 5 (4) | .78 |
| Dermatologic events | 6 (2) | 9 (7) | .006 |
| Bleeding | 1 (< 1) | 1 (< 1) | .46 |
| Other conditions | 22 (6) | 5 (4) | .66 |
IQR indicates interquartile range.